Gts Securities LLC Editas Medicine, Inc. Call Options Transaction History

Gts Securities LLC

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$4.67 - $7.28 $66,781 - $104,104	-14,300 Reduced 35.4%	26,100 $121,000
Q1 2024 May 15, 2024	BUY	$7.03 - $11.07 $89,281 - $140,589	12,700 Added 45.85%	40,400 $299,000
Q4 2023 Feb 14, 2024	BUY	$6.25 - $11.11 $21,250 - $37,774	3,400 Added 13.99%	27,700 $280,000
Q3 2023 Nov 15, 2023	BUY	$6.92 - $9.31 $168,156 - $226,233	24,300 New	24,300 $189,000

252

58.7M

494K

417K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $239M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

Stay updated on Gts Securities LLC with notifications on news.